市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Celcuity Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | NA |
| 内部交易活动 | 1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -1.0 |
| 平均 | 0.63 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HAHNE VICKY | 92.00 | - | 16,000 | 1,472,000 |
| LAING LANCE G. | 92.00 | - | 20,000 | 1,840,000 |
| SULLIVAN BRIAN F. | 92.00 | - | 80,000 | 7,360,000 |
| 累积净数量 | 116,000 | |||
| 累积净值 ($) | 10,672,000 | |||
| 累积平均购买 ($) | 92.00 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HAHNE VICKY | 职员 | 14 Aug 2026 | 获得 (+) | 16,000 | 92.00 | 1,472,000 |
| SULLIVAN BRIAN F. | 职员 | 14 Aug 2026 | 获得 (+) | 80,000 | 92.00 | 7,360,000 |
| LAING LANCE G. | 职员 | 14 Aug 2026 | 获得 (+) | 20,000 | 92.00 | 1,840,000 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合